These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
56 related articles for article (PubMed ID: 7697734)
1. Characterization of immune suppression by a synthetic HIV gp41 peptide. Wang H; Nishanian P; Fahey JL Cell Immunol; 1995 Apr; 161(2):236-43. PubMed ID: 7697734 [TBL] [Abstract][Full Text] [Related]
2. The immunosuppressive peptide of HIV-1: functional domains and immune response in AIDS patients. Denner J; Norley S; Kurth R AIDS; 1994 Aug; 8(8):1063-72. PubMed ID: 7986401 [TBL] [Abstract][Full Text] [Related]
3. HIV-1 neutralizing antibodies elicited by the candidate CBD1 epitope vaccine react with the conserved caveolin-1 binding motif of viral glycoprotein gp41. Rey-Cuillé MA; Svab J; Benferhat R; Krust B; Briand JP; Muller S; Hovanessian AG J Pharm Pharmacol; 2006 Jun; 58(6):759-67. PubMed ID: 16734977 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of protein kinase C and anti-CD3-induced Ca2+ influx in Jurkat T cells by a synthetic peptide with sequence identity to HIV-1 gp41. Ruegg CL; Strand M J Immunol; 1990 May; 144(10):3928-35. PubMed ID: 2139676 [TBL] [Abstract][Full Text] [Related]
5. The CBD1 peptide corresponding to the caveolin-1 binding domain of HIV-1 glycoprotein gp41 elicits neutralizing antibodies in cynomolgus macaques when administered with the tetanus T helper epitope. Benferhat R; Martinon F; Krust B; Le Grand R; Hovanessian AG Mol Immunol; 2009 Feb; 46(4):705-12. PubMed ID: 19010547 [TBL] [Abstract][Full Text] [Related]
6. Characterization of the interacting domain of the HIV-1 fusion peptide with the transmembrane domain of the T-cell receptor. Cohen T; Pevsner-Fischer M; Cohen N; Cohen IR; Shai Y Biochemistry; 2008 Apr; 47(16):4826-33. PubMed ID: 18376816 [TBL] [Abstract][Full Text] [Related]
7. Characterization of a novel human immunodeficiency virus type 1 neutralizable epitope within the immunodominant region of gp41. Viveros M; Dickey C; Cotropia JP; Gevorkian G; Larralde C; Broliden K; Levi M; Burgess A; Cao C; Weiner DB; Agadjanyan MG; Ugen KE Virology; 2000 Apr; 270(1):135-45. PubMed ID: 10772986 [TBL] [Abstract][Full Text] [Related]
8. The caveolin-1 binding domain of HIV-1 glycoprotein gp41 (CBD1) contains several overlapping neutralizing epitopes. Benferhat R; Krust B; Rey-Cuillé MA; Hovanessian AG Vaccine; 2009 Jun; 27(27):3620-30. PubMed ID: 19464543 [TBL] [Abstract][Full Text] [Related]
9. The immunogenic CBD1 peptide corresponding to the caveolin-1 binding domain in HIV-1 envelope gp41 has the capacity to penetrate the cell membrane and bind caveolin-1. Benferhat R; Sanchez-Martinez S; Nieva JL; Briand JP; Hovanessian AG Mol Immunol; 2008 Apr; 45(7):1963-75. PubMed ID: 18054388 [TBL] [Abstract][Full Text] [Related]
10. Anti-HIV activity of multibranched peptide constructs derived either from the cleavage sequence or from the transmembrane domain (gp41) of the human immunodeficiency virus type 1 envelope. Sabatier JM; Mabrouk K; Moulard M; Rochat H; Van Rietschoten J; Fenouillet E Virology; 1996 Sep; 223(2):406-8. PubMed ID: 8806580 [TBL] [Abstract][Full Text] [Related]
11. Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay. Opalka D; Pessi A; Bianchi E; Ciliberto G; Schleif W; McElhaugh M; Danzeisen R; Geleziunas R; Miller M; Eckert DM; Bramhill D; Joyce J; Cook J; Magilton W; Shiver J; Emini E; Esser MT J Immunol Methods; 2004 Apr; 287(1-2):49-65. PubMed ID: 15099755 [TBL] [Abstract][Full Text] [Related]
12. HIV envelope glycoprotein-induced cell killing by apoptosis is enhanced with increased expression of CD26 in CD4+ T cells. Jacotot E; Callebaut C; Blanco J; Rivière Y; Krust B; Hovanessian AG Virology; 1996 Sep; 223(2):318-30. PubMed ID: 8806567 [TBL] [Abstract][Full Text] [Related]
13. T21/DP107, A synthetic leucine zipper-like domain of the HIV-1 envelope gp41, attracts and activates human phagocytes by using G-protein-coupled formyl peptide receptors. Su SB; Gao Jl; Gong Wh; Dunlop NM; Murphy PM; Oppenheim JJ; Wang JM J Immunol; 1999 May; 162(10):5924-30. PubMed ID: 10229829 [TBL] [Abstract][Full Text] [Related]
14. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor. Deng Y; Zheng Q; Ketas TJ; Moore JP; Lu M Biochemistry; 2007 Apr; 46(14):4360-9. PubMed ID: 17371053 [TBL] [Abstract][Full Text] [Related]
15. Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization. Spear GT; Takefman DM; Sharpe S; Ghassemi M; Zolla-Pazner S Virology; 1994 Nov; 204(2):609-15. PubMed ID: 7941328 [TBL] [Abstract][Full Text] [Related]
16. Role of the fusion peptide and membrane-proximal domain in HIV-1 envelope glycoprotein-mediated membrane fusion. Dimitrov AS; Rawat SS; Jiang S; Blumenthal R Biochemistry; 2003 Dec; 42(48):14150-8. PubMed ID: 14640682 [TBL] [Abstract][Full Text] [Related]
17. Quaternary protein mimetics of gp41 elicit neutralizing antibodies against HIV fusion-active intermediate state. Sadler K; Zhang Y; Xu J; Yu Q; Tam JP Biopolymers; 2008; 90(3):320-9. PubMed ID: 18338371 [TBL] [Abstract][Full Text] [Related]
18. HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb. McGaughey GB; Citron M; Danzeisen RC; Freidinger RM; Garsky VM; Hurni WM; Joyce JG; Liang X; Miller M; Shiver J; Bogusky MJ Biochemistry; 2003 Mar; 42(11):3214-23. PubMed ID: 12641452 [TBL] [Abstract][Full Text] [Related]
19. Interactions of HIV-1 antibodies 2F5 and 4E10 with a gp41 epitope prebound to host and viral membrane model systems. Veiga AS; Pattenden LK; Fletcher JM; Castanho MA; Aguilar MI Chembiochem; 2009 Apr; 10(6):1032-44. PubMed ID: 19283693 [TBL] [Abstract][Full Text] [Related]
20. HIV-1 envelope protein is expressed on the surface of infected cells before its processing and presentation to class II-restricted T lymphocytes. Callahan KM; Rowell JF; Soloski MJ; Machamer CE; Siliciano RF J Immunol; 1993 Sep; 151(6):2928-42. PubMed ID: 8376762 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]